
Semaglutide, a GLP-1 receptor agonist, significantly reduced cardiovascular outcomes in individuals with overweight or obesity. A review of 38 studies revealed a 76% decrease in hospitalization due to heart failure, a 17% reduction in cardiovascular-related deaths, and a 21% decrease in all-cause mortality. Additionally, there were notable reductions in coronary revascularization and non-fatal myocardial infarction by 24%. While semaglutide also decreased stroke risk in diabetic patients by 35%, it was associated with a higher incidence of adverse effects. These findings highlight semaglutide's potential benefits for cardiovascular health, alongside the need for monitoring adverse effects during treatment.
Like
Save
Share